DNA polymerase (human) (POL (commonly followed by Greek letter or family designation, e.g., POLA for polymerase alpha, POLH for polymerase eta; "DNA polymerase" itself is a general term))

DNA polymerases in humans are a diverse family of enzymes that catalyze the synthesis of DNA from deoxyribonucleotide triphosphates, playing central roles in chromosomal replication and various forms of DNA repair. Replicative polymerases (alpha, delta, epsilon) ensure accurate genome duplication and cell division, while specialized DNA repair polymerases (e.g., beta, lambda, eta, kappa, iota, mu, terminal deoxynucleotidyl transferase) enable tolerance of DNA damage and maintenance of genomic stability through repair pathways or translesion synthesis. DNA polymerases are critical drug targets in cancer chemotherapy (via nucleoside analogs) and antiviral therapies. Defects or dysregulation can lead to disease such as cancer, immunodeficiency (e.g., xeroderma pigmentosum variant from POLH mutations), or other genome instability syndromes. Each human DNA polymerase has unique substrate specificity, fidelity, processivity, and cellular function—therapeutic targeting thus requires careful, polymerase-specific consideration.

Other names

DNA polymerase (generic)DNA polymerase alpha (POLA)DNA polymerase delta (POLD)DNA polymerase epsilon (POLE)DNA polymerase eta (POLH)DNA polymerase iota (POLI)DNA polymerase kappa (POLK)DNA polymerase lambda (POLL)DNA polymerase mu (POLM)DNA polymerase beta (POLB)Terminal deoxynucleotidyl transferase (TdT)

Competitive inhibition at nucleotide binding site (nucleoside/nucleotide analogs compete with normal substrates); Chain termination (drugs cause premature termination of DNA chain); Error induction or stalling (some drugs make polymerase incorporate errors or stall at lesions); Allosteric modulation (rare, some inhibitors)